{"id":53544,"name":"SANOTIZE RESEARCH & DEVELOPMENT CORPORATION","slug":"sanotize-research-development-corporation","state":"BC","country":"Canada","description":"Development of anti-microbial medicines from nitric oxide","totalSpending":120000,"filings":9,"yearlySpending":[{"year":2022,"income":18000},{"year":2023,"income":72000},{"year":2024,"income":30000}],"issues":["HCR","MED","BUD"],"firms":["DAVID GENCARELLI"],"lobbyists":["DAVID GENCARELLI"],"govEntities":["Defense Threat Reduction Agency (DTRA)","HOUSE OF REPRESENTATIVES","SENATE","Defense, Dept of (DOD)","Centers For Disease Control & Prevention (CDC)","Centers For Medicare and Medicaid Services (CMS)","Defense Advanced Research Projects Agency (DARPA)"],"sampleDescriptions":["Legislation related to funding for FDA-required trials of a medical device Consultation with United States Health agencie and Military Health Commands about research and development of medicines and m","Seeking funding for Phase III trials of client health product through Congressional appropriations process, specifically the 2023 Omnibus legislation.","Effort to Seek funding for Phase II trials of clients product through the appropriations process, specifically the 2023 Omnibus legislation.","Seeking US federal funding for Phase III trials of client health product through congressional appropriations process, specifically the 2023 Omnibus legislation.","Outreach to Senate HELP committee and House energy & Commerce seeking support for grant research grant efforts with HHS agencies"],"years":[2022,2023,2024]}